Research programme: rheumatoid arthritis gene therapies - Arthrogen

Drug Profile

Research programme: rheumatoid arthritis gene therapies - Arthrogen

Alternative Names: AAV5.NF-kB.IFN-β; ART-D01; ART-G01; ART-I02; ART-T01; ART-T02; rAAV5.interferon-β.stuffer; Recombinant AAV type2/5 - hIFN-b gene

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator Arthrogen
  • Class Gene therapies
  • Mechanism of Action Chemokine inhibitors; Gene transference; Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 06 Apr 2016 Arthrogen and Centre for Human Drug Research plans a phase I trial for Rheumatoid arthritis in Netherlands (Intra-articular) (NCT02727764)
  • 17 Jan 2011 Preclinical development is ongoing Netherlands
  • 13 Jun 2009 Pharmacokinetics data from a preclinical trial in rheumatoid arthritis presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top